Differentiated outcomes start with differentiated design

The SAPIEN 3 Ultra valve is built on the proven SAPIEN 3 platform.

Edwards Commander delivery system

Predictability and control to meet the increasing complexity of your procedures.

Single-digit new permanent
pacemaker rates1

6.6%
at 30 days
7.5%
at 1 year
0.6%1
stroke rate
99%3
deployment
accuracy

Resource Center

View All Resources

References:  

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.
2. Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.
3. The PARTNER II Trial intermediate-risk cohort 30-day unadjusted clinical event rates for TAVR with the SAPIEN 3 valve, AT population (n=1077). Data on file.